The American Association for Cancer Research’s annual conference kicked off Friday as more than 20,000 attendees descend on San Diego. Analysts and researchers who spoke with BioSpace said they’re looking forward to early scientific data, and antibody-drug conjugates (ADCs) will be a key focus.
Stay tuned to BioSpace as we keep you updated on all of the biggest data and news from the conference.
Updated April 7, 8:00 p.m. EST/5:00 p.m. PST:
Regeneron Touts Durability of Multiple Myeloma Candidate
Regeneron buttressed its regulatory case for linvoseltamab, an investigational bispecific antibody, with the presentation of positive pivotal data from the Phase I/II LINKER-MM1 trial in relapsed/refractory (R/R) multiple myeloma.
After 11 months of follow-up, treatment with the candidate elicited a 71% objective response rate (ORR), with 46% of patients seeing a complete response or better and 62% achieving a very good partial response or better, Regeneron reported. Median times to reach these metrics were eight months and three months, respectively. After 12 months, the estimated probability of maintaining a response was 78%, progression-free survival was 69% and overall survival was 75%. None of these measures were reached, and Regeneron stated that these data “reinforce [a] high response rate that deepens over time in patients with heavily pre-treated multiple myeloma.”
Linvoseltamab’s safety profile in the Phase I/II LINKER-MM1 trial was less positive, with 85% of patients treated with a 200-mg dose experiencing Grade 3 or worse adverse events (AE), Regeneron reported in December 2023. Fourteen patients—12% of the patient population—died due to treatment-emergent AEs, of which 11 were due to infections.
The FDA in February accepted the Biologics License Application for linvoseltamab in fourth-line R/R multiple myeloma. The candidate is also under review with the European Medicines Agency.
BioNTech/Genentech Cancer Vaccine 'Persistent' in Pancreatic Cancer
BioNTech and Genentech’s messenger RNA (mRNA) cancer vaccine candidate, autogene cevumeran, or BNT122/RO7198457, continued to show promise in a particularly difficult-to-treat form of pancreatic cancer three years after treatment, according to an oral presentation Sunday at AACR. Specifically, patients with resected pancreatic ductal adenocarcinoma (PDAC) continued to see polyspecific T-cell responses and delayed tumor recurrence.
Persistence of T cells “was associated with a longer median recurrence-free survival in cancer vaccine responders,” BioNTech reported in a press release. The company called the results an “early signal” of the candidate’s potential in this indication. PDAC carries a 5-year overall survival rate of only 8% to 10%.
Autogene cevumeran, being jointly developed by BioNTech and Genentech, is currently being studied in three ongoing Phase II clinical trials in adjuvant PDAC, first-line melanoma and adjuvant colorectal cancer.
Opdivo Shows Promise in Neoadjuvant Pancreatic Cancer
Bristol Myers Squibb’s PD-1 inhibitor Opdivo, when combined with several types of chemotherapy prior to surgery, may improve outcomes for pancreatic cancer patients, a pilot study presented at AACR’s annual meeting on Sunday revealed.
The study observed 24 of the 28 trial participants who were given the Opdivo and chemotherapy combination before surgery and had no grade 2 post-operative fistulas. After two years, the combination led to a median progression-free survival rate of 34.8 months; the median overall survival rate was recorded at 35.1 months. No unexpected safety signals were reported, and the addition of Opdivo did not increase the rates of grade three adverse events.
This is the first trial reported of a PD1 inhibitor in neoadjuvant pancreatic cancer, according to the abstract. A Phase II trial is underway.
https://www.biospace.com/article/aacr-2024-what-cancer-researchers-are-talking-about/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.